WO2012083099A1 - Biologically-active radiolabeled cry1fa and receptor binding assay methods - Google Patents
Biologically-active radiolabeled cry1fa and receptor binding assay methods Download PDFInfo
- Publication number
- WO2012083099A1 WO2012083099A1 PCT/US2011/065322 US2011065322W WO2012083099A1 WO 2012083099 A1 WO2012083099 A1 WO 2012083099A1 US 2011065322 W US2011065322 W US 2011065322W WO 2012083099 A1 WO2012083099 A1 WO 2012083099A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cry
- protein
- labeled
- toxin
- brush border
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
- C07K14/325—Bacillus thuringiensis crystal peptides, i.e. delta-endotoxins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
- Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants
Definitions
- the general field of the invention is the area of life sciences, particularly agricultural sciences and testing methods.
- the field of the invention is the biochemistry and mode of action of Bacillus thuringiensis crystalline (Cry) endotoxins and their interactions with insect Cry toxin receptors.
- Cry insecticidal proteins are endotoxins produced by Bacillus thuringiensis (Bt), a Gram positive bacterium found globally distributed in different soil types. Various classes of Cry proteins are selectively toxic against certain insect pests. The endotoxin is typically found in the form of a crystalline protein located in large inclusion bodies of the bacterium. Cry toxins have considerable sequence diversity (Crickmore et ah, 1998; de Maagd et ai, 2003), but the majority of the toxins that have activity against lepidopteran pests are 130 kDa protoxins having a three domain active core toxin structure (de Maagd et ai , supra).
- the subject of the current invention relates to the Cry 1 Fa toxin, a three domain Cry protein.
- This toxin has demonstrated insecticidal activity against various lepidopteran insects, including Spodoptera frugiperda (J. E. Smith) (fall armyworm) and Osirinia nubilalis (Hilbner) (European corn borer), which are two of the most economically important insect pests of maize.
- Cry 1 Fa is the toxin component of two USDA deregulated transgenic plant incorporated pesticides know as event TCI 507 in maize (HERCULEX ® ) and event 281-24- 236 in cotton (WIDESTRIKE ® ).
- Cry 1 Fa full-length holotoxin protein requires proteolytic cleavage at both the N-terminus and the C-terminus ends for activation of its insecticidal activity.
- the midguts of lepidopteran insects contain a variety of trypsin and chymotrypsin-like proteases that process the full length holotoxin to a core toxin structure having a size of approximately 68 kDa (Christeller et al., 1992; Gatehouse et ai, 1997; Bernardi et al, 1996).
- the processing involves removal of approximately 28 amino acids from the N -terminus and approximately 530 amino acids from the C-tcrminus (protoxin segment), and the resulting core toxin segment is released and binds to specific receptors located within the insect gut.
- insects can develop resistance to the activity of Cry protein toxins through changes in midgut localized receptors that bind the Cry protein core toxin (Heckel et al, 2007; Van Rie et al , 1990b). Further, other mechanisms of resistance development have been documented, including: reduced activation of the protoxin, changes in the number of Cry receptors in the insect midgut, and the loss of the ability to respond to the toxin In ⁇ formation of membrane pores that contribute to insect mortality (see Griffitts and Aroian, 2005; and Van Rie et al, 1990b).
- Palmer et al. (1997) described an indirect method of radioactive labeling of proteins specifically at cysteine residues.
- an intermediate compound, fluorescein-5-maleimide is first reacted with radio-iodine, then the radiolabeled fluorescein- 5-maleimide is used to chemically modify the protein at available cysteine residues.
- This invention describes the use of the highly specific Palmer et al. method to radiolabel Cry 1 Fa protein by targeting a single cysteine residue (C205) located in Domain 1 of the Cry 1 Fa core toxin.
- the non-traditionally radiolabeled Cryl Fa protein was found to bind to receptors in a saturable manner, and was used in a competitive binding assay to determine if other Cry toxins compete with its binding. Using this assay it was demonstrated that field resistance to CrylFa toxin that developed in a population of S. frugiperda collected in Puerto Rico is due to the loss of the ability of receptors in BBMVs of these insects to bind CrylFa core toxin protein.
- Figure 1 is a bioassay of trypsin-truncated CrylFa and fluorescein-5-malemide labeled, trypsin-truncated CrylFa against S. frugiperda larvae.
- the figure summarizes the results of insect diet bioassays with Spodoptera frugiperda neonate larvae using iodinated (nonradioactive) CrylFa core toxin protein prepared by the method of the current invention.
- FIG. 2 shows saturation binding curves of radio-iodinated CrylFa core toxin protein to European Corn Borer (ECB) BBMVs.
- the figure depicts the saturation binding of radioiodinated Cry 1 Fa core toxin protein prepared by the method of the current invention to BBMVs prepared from Oslrinia nubilalis larval midguts.
- SEQ ID NO: l is the synthetic DNA sequence encoding CrylFa holotoxin.
- SEQ ID NO:2 is the CrylFa holotoxin.
- Domain I is composed of seven a-helices which are believed to insert into the membrane of the insect midgut and form a pore-like structure (Ballester et al., 1999). Domain II consists of three antiparallel ⁇ -sheets, and Domain III forms a ⁇ -sandwich structure (Pigott and Ellar, 2007).
- Quantitative biochemical assays provide a means to measure the interaction of Cry toxins with receptor proteins found in insect midguts.
- saturation type binding assays the labeled Cry toxin protein (ligand) is incubated in buffer solutions that promote the binding of the Cry toxin protein to an insect receptor protein.
- a saturation binding assay a fixed amount of insect receptor protein (commonly brush border membrane vesicles prepared from insect midguts) is mixed (in separate tubes) with increasing amounts of iodinated Cry toxin protein, and allowed to react for a set amount of time.
- Unbound Cry protein that is, not bound to an insect receptor protein
- Unbound Cry protein is separated from bound protein by one of various methods, and the amount of radioactivity in the bound protein fraction provides an indication of the amount of Cry protein bound to the insect receptor.
- One skilled in the field of biochemistry will realize that an observation of little or no bound radioactivity will indicate the lack of a receptor for the particular Cry toxin being studied in the insect species from which the receptor preparation was made.
- a second embodiment of a binding assay is a competitive assay.
- the radioactive Cry toxin protein is mixed with an excess of a second, nonradioactive Cry protein, and the Cry proteins are allowed to bind under standard conditions to insect receptor proteins. If the second, non radioactive Cry toxin protein is able to compete with the radioactive Cry toxin protein for binding to the insect receptor, then the radioactive protein will be displaced from the receptor binding site, and little radioactivity will be recovered in the bound state. If the nonradioactive and the radioactive Cry toxin proteins bind to different insect receptor proteins, then they will not compete with one another in binding to the same insect receptor protein.
- the amount of radioactivity recovered in the bound protein fraction will be the same, or nearly the same, as when the nonradioactive second Cry toxin protein was not present in the binding reaction.
- Various methods are available to quantify the amount of radioactivity in the bound protein fraction.
- frugiperda collected in Puerto Rico can be explained by the inability of receptors in brush border membrane vesicles from these insects to bind Cry 1 Fa core toxin.
- Nucleic acid sequences are presented in the standard 5' to 3' direction, and protein sequences are presented in the standard amino (N) terminal to carboxy (C) terminal direction.
- Cry 1 Fa toxin a chimeric toxin protein
- SEQ ID NO:2 a chimeric toxin protein
- CDS plant-optimized coding sequence
- pDAB 1817 is derived from pMYC1803 (US Patent No. 7338794).
- the basic cloning strategy entailed ligating a DNA fragment, flanked by Spel d Kpnl restriction enzyme recognition sites and containing the Cry 1 Fa toxin CDS, to the large fragment of pMYC1803 prepared by cleaving pMYC ' 1803 DNA with Spel and Kpnl restriction enzymes.
- Plasmid pMYC1803 is a medium copy plasmid derived from the RSFlOlO-based plasmid pTJS260 (see US Patent No.
- the Cry 1 Fa toxin CDS was placed under the expression control of the Ptac promoter and the rrnBTlT2 terminator from plasmid pK 223-3 (PL Pharmacia, Milwaukee, Wl).
- the expression plasmid pDAB 1 817 was transformed by electroporation into P. fluorescens strain MB217 (a derivative of strain MB 101 ; P. fluorescens biovar I), with selection for resistance to tetracycline. Recombinant colonics were identified by restriction digestion f miniprep plasmid DNA.
- IB Protein inclusion bodies
- a MALDI-R (Reflectron) mass spectrometer from Micromass (Milford, MA) was used to measure peptide masses in accordance with the manufacturer's prescribed methods and recommendations. Frozen cell pellets were thawed in a room temperature water bath. The cells were resuspended to 10% w/v in lysis buffer (50 mM Tris HC1, pH7.5; 200 mM NaCl; 5% Glycerol; 2 mM EDTA disodium salt (Ethylenediaminetetraacetic acid); 0.5% Triton X- 100; and 1 mM DTT (dithiothreitol-added just prior to use)). 25 ml.
- lysis buffer 50 mM Tris HC1, pH7.5; 200 mM NaCl; 5% Glycerol; 2 mM EDTA disodium salt (Ethylenediaminetetraacetic acid); 0.5% Triton X- 100; and 1
- protease inhibitor cocktail (Sigma- Aldrich) was added for every 100 gm of cell paste treated.
- the slurry was passed twice through a Microfluidics Micro fluidizer at 12000+ psi (Microfluidics Intern. Corp., Newton, MA).
- the lysate was centrifuged at 18000 x g at 4° for 30 min, and the supernatant was retained.
- the inclusion pellet was washed in lysis buffer without protease inhibitor cocktail until no bacterial odor remained (usually 2 or 3 washes), by gently homogenizing using a spatula or mechanical mixer (to about 10%> w/v solids) and
- the samples were then diluted 10X and 20X with Laemmli sample buffer without DTT and 10 ⁇ were loaded onto a Criterion 18 well 10% Bis-Tris gel (Bio-Rad Inc.) run with IX NuPAGE MES buffer (Invitrogen). Gels were run for 5 min at 100V and then 45 min at 200V. Gels were rinsed and washed in water for 20 min and stained with Simply Blue SafeStainTM. Quantification of target bands was done by comparing densitometric values for the bands against a series of Bovine Serum Albumin (BSA) standard samples run on the same gel, and scanned to generate a densitometric standard curve.
- BSA Bovine Serum Albumin
- Truncation and purification of CrylFa core toxin protein Purified inclusion bodies were washed with sterile water, then solubilized in 20 mM CAPS, pHl 1 (3- (cyclohexamino) 1 -propanesulfonic acid) containing 10 mM DTT by rocking the protein solution for 1 hr at room temperature. After removing insoluble material by centrifugation (30000 x g for 30 min at 4°), trypsin treated with 0.5% (w/v) tosyl phenylalanyl chloromethyl ketone (TPCK) (Sigma- Aldrich) was added to the supernatant.
- TPCK tosyl phenylalanyl chloromethyl ketone
- SDS-PAGE analysis of purified CrylFa core toxin SDS-PAGE analysis of trypsin truncated CrylFa toxin protein was conducted under reducing and denaturing conditions by the method of Laemmli (as per Sambrook et al, supra). Reduction of the proteins was achieved using 5% ⁇ -mercaptoethanol, and heat denaturation was performed at 90° for 5 minutes in the presence of 2% SDS. Proteins were loaded into wells of a 4% to 20% Tris-glycine polyacrylamide gel (Invitrogen) and separated at 200 volts for 60 minutes.
- Protein bands were stained with Coomassie Brilliant Blue R-250 (Bio-Rad) for one hour, and then destained with a solution of 5% methanol in 7% acetic acid in the presence of cellulose sponges.
- the gels were imaged and analyzed using a Bio-Rad Fluro-S Multi ImagerTM with Quantity OneTM imaging software.
- Relative molecular weights of the protein bands were determined by including a sample of BenchMarkTM Protein Ladder (Life Technologies, Rockville, MD) or See BlueTM prestained molecular weight marker (Invitrogen) in one well of the gel.
- CrylFa core toxin protein Previous work demonstrated that iodination of CrylFa toxin protein destroyed the capacity of the iodinated protein to bind to its receptor(s) in insect brush border membrane vesicles (BBMVs), as well as the insect toxicity of the protein (Luo et ah, 1999). In that study, CrylFa toxin protein was radio- iodinated using a standard iodination bead method (Pierce lodination Beads; Thermo Fisher Scientific), and binding studies revealed that the protein had lost all of its ability for specific binding to receptor(s) in BBMVs from S. exigna and S.fr giperda. Further, when non- radiolabeled Nal was used to iodinate CrylFa toxin protein employing the Iodination Bead method, the iodinated CrylFa was found to have lost its insecticidal activity against
- Iodination of proteins by Iodination Bead protocols takes place at positions ortho to the hydroxy] group on tyrosine; mono- or di-substitution can occur.
- the positions of iodination depend on the placement of tyrosine residues within the subject protein, and multiple iodinations may have the consequence of disruption of the protein's structure and/or function.
- the CrylFa core toxin segment comprises 20 tyrosine residues, which may serve as iodination targets.
- trypsin truncated CrylFa core toxin protein can be specifically fluorcscently labeled at the cysteine corresponding to the C205 residue of the Cryl Fa toxin protein using fluorescein-5-maleimide, and that the tluorescently labeled protein is biologically active, causing insect mortality at dosages equal to those of nonlabeled, trypsin truncated CrylFa core toxin.
- the Cry 1 Fa core toxin segment contains three cysteine amino acid residues, at positions 9, 14, and 205. Truncation of the protein by trypsin treatment removes C9 and C14, providing a core toxin segment that retains the cysteine corresponding to the C205 residue. Palmer et al. (1997) demonstrated that the phenyl rings of fluorescein-5-maleimide can be radio-iodinated and then reacted with proteins that contain sulfhydryl groups (e.g. as provided by free cysteine residues), resulting in alkylation of the free cysteines in the protein, and thus providing a radioactively labeled protein.
- the trypsin-truncated CrylFa core toxin contains a single cysteine residue at the position corresponding to C205, and thus provides a substrate for alkylation and radiolabeling of the protein at a single (specific) site.
- Fluoresccin-5-maleimide was dissolved to 10 raM in DM SO (Dimethyl Sulfoxide), then diluted to 1 mM in phosphate buffered saline (PBS; 20 mM sodium phosphate, 0.15 M NaCl, pH7.5), as determined by the molar extinction coefficient of F 5-M (68,000 ' ⁇ "1 ).
- PBS phosphate buffered saline
- 0.5 mCi of Na 123 ! was added behind lead shielding.
- the reaction mixture was added to a ZebraTM spin column (Invitrogen) equilibrated in 20 mM CAPS, 150 mM KG, pH9, and centrifuged at 1500 x g for 2 min to separate non-reacted iodinated dye from the protein.
- the I radiolabeled fluorescein-CrylFa core toxin protein was counted in a gamma counter to determine its specific radioactivity, assuming 80% recovery of the input toxin protein.
- the specific activity of the radiolabeled Cry 1 Fa core toxin protein was approximately 1.1 ⁇ / ⁇ protein. This specific activity was low compared to typical expected levels of labeling of similarly-sized proteins using the Iodination Bead procedure. This is presumably due to a single site of labeling (corresponding to C205), and to the (possibly) relative inaccessibility of that site, which is presumed to be located deep within Domain I of the core toxin segment (based upon localization using a comparison crystal structure of the Cryl Aa protein).
- the radiolabeled protein was also characterized by SDS-PAGE and visualized by phosphor-imaging to validate that the radioactivity measured was covalently associated with the Cryl Fa core toxin protein.
- Radio-purity of the radio-iodinated Cryl Fa core toxin protein (and subsequent detection of Cryl Fa bound to its BBMV receptor) was determined by SDS- PAGE, phosphor-imaging and gamma counting.
- Coomassie stained SDS-PAGE gels were imaged by wrapping them in MylarTM film (12 ⁇ thick), and exposing them under a Molecular Dynamics (Sunnyvale, CA) storage phosphor screen (35 cm x 43 cm) for 1 hour.
- the plates were developed using a Molecular Dynamics Storm 820 phosphor-imager and the image analyzed using ImageQuantTM software.
- the radioactive band along with areas immediately above and below the band were cut from the gel using a razor blade and counted in a gamma counter. Radioactivity was detected in the Cryl Fa core toxin protein band and in areas below the band. No radioactivity was detected in the gel region above the Cryl Fa core toxin protein band. Some radioactivity was detectable in the gel region below the Cry 1 Fa core toxin protein band (i.e. fragments smaller than the Cry 1 Fa core toxin protein). These radioactive contaminants likely represent degradation products of the Cry 1 Fa core toxin protein.
- Fluorescently labeled (non-radioactive, iodinated) Cry 1 Fa core toxin protein thus prepared was used in insect diet feeding bioassays to demonstrate that insect toxicity had not been affected, and radio-iodinated (fluorescently labeled) Cry 1 Fa core toxin protein was used in binding studies with BBMV preparations to demonstrate that receptor binding activities had not been affected.
- Trypsin- truncated Cry 1 Fa core toxin proteins either non -radioactive iodine fluorescein-5-maleimide labeled, or unlabeled, were individually tested for their insecticidal activity in a top load diet bioassay against larvae of Spodoptera frugiperda (fall armyworm; FAW) Larvae of F A W were hatched from eggs obtained from a colony maintained by a commercial insectary (Benzon Research Inc., Carlisle, PA).
- the bioassays were conducted in 128-well plastic trays specifically designed for insect bioassays (C-D International, Pitman, NJ). Each well contained 0.5 mL of Multi- species Lepidoptera diet (Southland Products, Lake Village, AR). A 40 xL aliquot of the purified Cry 1 Fa core toxin protein, diluted to various concentrations in 10 mM CAPS, pH10.5, or 40 xh of a control solution, were delivered by pipette onto the diet surface of each well (26.7 Sixteen wells were tested per sample. The negative control was a CAPS buffer solution blank containing no protein. Positive controls included preparations of full length Cry 1 Fa toxin.
- the treated trays were held in a fume hood until the liquid on the diet surface had evaporated or was absorbed into the diet. Diet concentrations of the Cry 1 F toxin proteins were calculated as the amount (ng) of Cry IF toxin protein per square centimeter of surface area in the well (1.5 cm ).
- GI [1 - (TWIT/TNIT)/(TWIBC/TNIBC)]
- TWIT is the Total Weight of Insects in the Treatment
- TNIT is the Total Number of Insects in the Treatment
- TWIBC is the Total Weight of Insects in the Background Check (Buffer
- TNIBC Total Number o Insects in the Background Check (Buffer
- the GI 5 o was determined to be the concentration of Cry 1 Fa toxin protein in the diet at which the GI value was 50%; i.e. the growth of the insects on Cry 1 Fa-containing diet was only half that of the insects on diet with no CrylFa protein, as calculated above.
- the LC50 50% Lethal Concentration; calculated as the concentration of CrylFa toxin protein in the diet at which 50% of test insects were killed) was not determined, as very little mortality was observed during the 5 day experimental period.
- Statistical analysis is done using JMP software (SAS, Gary, NC).
- cocktail components were AEBSF (500), EDTA (250), Bestatin (32), E-64 (0.35), Leupeptin (0.25), and Aprotinin (0.075).
- the tissue was homogenized with 15 strokes of a glass tissue homogenize!-.
- BBMVs were prepared by the MgCL precipitation method of Wolfersberger (1993). Briefly, an equal volume of a 24 mM MgCl 2 solution was mixed with the midgut homogenate, stirred for 5 minutes and allowed to stand on ice for 20 min. The solution was centrifuged at 2500 x g for 15 min at 4°. The supernatant was saved and the pellet suspended into 0.5X volume of homogenization buffer and centrifuged again.
- BBMV Storage Buffer (10 mM HEPES pH7.4 (4-(2- hydroxyethy 1)- 1 -pipcrazineethanesul onic acid), 130 mM KG, 10% glycerol)
- Binding of 125 I-CrylFa core toxin protein to BBMVs To determine the optimal amount of BBMV protein to use in competitive binding assays, a saturation curve was generated. l2i l radiolabeled Cry 1 Fa core toxin protein (0.5 nM) was incubated for 1 hr at 28° with (). nubilalis (ECB) BBMV proteins in concentrations ranging from 0 to 500 ⁇ g/m ⁇ . in binding buffer (8 mM NaHPO.,, 2 mM KH 2 P0 4 , 150 mM NaCl, 0.1% BSA, pH7.4). Total volume was 0.5 mL.
- Bound I-CrylFa core toxin protein was separated from unbound material by sampling 150 xL of the reaction mixture in triplicate and centrifuging the samples at 14000 x g for 8 min at room temperature. The supernatant was gently removed, and the pellet washed three times with ice cold binding buffer. The bottom of the centrifuge tube containing the pellet was cut off and placed into a 13 x 75 -mm glass culture tube. Each sample was counted for 10 min in a gamma counter. The value of counts-per-minute (CPM) minus background (reactions with no added protein) was plotted versus BBMV protein concentration. The optimal range of BBMV protein to use in each binding reaction was determined to be 100 ng/ml, to 150 ⁇ g/mL.
- Binding kinetics To determine the binding kinetics, a saturation curve was generated. Briefly, 150 ⁇ g/mL of ECB BBMV proteins were incubated for 1 hr at 28° with increasing concentrations (ranging from 0.5 nM to 20 nM) of l25 I-CrylFa core toxin protein. Total binding was determined by sampling 150 ⁇ ⁇ of each concentration in triplicate, followed by cenlrifuging and counting as described above. The triplicate values were averaged. Non-specific binding was determined in the same manner, with the addition of 1 ,000 nM of non-radioactive (competitor) Cry 1 Fa core toxin protein.
- This concentration was at least 50-fold higher than the highest concentration of the radiolabeled Cry 1 Fa core toxin protein used; thus it would be expected to bind to all available receptor sites, while displacing the radiolabeled Cry 1 Fa core toxin protein.
- Specific binding was calculated as the difference in CPM (minus background) between total binding and non-specific binding. It was determined (Figure 2) that I-Cry l Fa core toxin protein specifically bound to the ECB BBMV proteins in a saturable manner, with a 3 ⁇ 4 of 1 1 nM and a B max of 37 fmoles/mg of ECB BBMV proteins. The level of non-specific binding was nearly 70% of total binding; however the level of specific binding clearly saturated, showing that the interaction was a receptor-mediated binding response.
- a "pull-down" type receptor assay was used to determine the amount of competition for binding to receptor sites between radiolabeled Cry 1 Fa core toxin protein and other (non labeled) Cry toxin proteins.
- the relative molecular size of the bound ligand with receptor was characterized by separation by SDS-PAGE, and the amount of radiolabeled ligand bound to the BBMV receptor was measured by detection of radioactivity in the gel by phosphor-imaging.
- Homologous and heterologous competition binding assays were conducted using 100 ⁇ g/mL or 150 ⁇ g/mL of BBMV protein (from various insect sources) and 0.5 nM or 2.5 nM of I-CrylFa core toxin protein.
- the competitive ligand i.e. 1000 nM of non-radiolabeled Cry toxin protein
- the competition ligand i.e. 1000 nM of non-radiolabeled Cry toxin protein
- incubations were carried out for 1 hr at 28°, and the 125 I-Cryl Fa core toxin protein bound to its BBMV receptor(s) was separated from nonbound protein by centrifuging the reaction mixture as described above.
- the pellet was washed three times with ice cold binding buffer, then solubilized by adding 25 of 2X Laemmli buffer with 5% ⁇ -mercaptoethanol, and rapidly mixing the sample for 10 min at 95°.
- the sample was centrifuged and duplicate samples were loaded onto a 4% to 20% Tris glycine polyacrylamide gel and separated by SDS-PAGE.
- the amount of 123 I-CrylFa core toxin protein bound to receptor was measured by phosphor-imaging of the gel and densitometry of the bands corresponding to radioactive Cryl Fa core toxin protein after a 3 day exposure of the plate.
- FAW insects resistant to Cryl Fa toxin [00501 Pull-down competitive binding assays were performed using BBMVs prepared from insect larvae that are resistant to intoxication by ingested Cry 1 Fa toxin.
- Cry 1 Fa- resistant larvae of S. frugiperda (rFAW)) were hatched from eggs harvested from a proprietary colony (Dow AgroSciences LLC, Indianapolis, FN). The rFAW larvae are more than 30-fold resistant to the toxicity of Cry 1 Fa toxin.
- BBMVs were prepared from rFAW larvae in the same manner as from their Cry 1 Fa-sensitive counterparts.
- BBMVs from wild type (i.e. Cry 1 Fa-sensitive) FAW larvae bound 125 I-CrylFa, and the binding could be displaced by 2000-fold addition of non-labeled Cryl Fa protein.
- BBMVs prepared from rFAW larvae and used in pull-down binding assays at 1 0 .ug/mL with 2.5 nM 12" l-Cryl Fa did not bind any of the 125 l-CrylFa core toxin protein.
- the resistance to Cryl Fa toxin in rFAW may be due to the inability of the Cryl Fa receptor(s) in the BBMVs to bind Cryl Fa core toxin protein.
- the resistance may be a result of absence of the receptors from the insects. In any case, it appears that the mechanism of resistance to Cryl Fa toxin in these rFAW larvae is receptor based.
- BBMVs prepared from insect larvae that are resistant to intoxication by ingested Cryl Fa toxin.
- Cryl Fa- resistant larvae of O. nubilalis rECB
- the rECB larvae are more than 30-fold resistant to the toxicity of Cryl Fa toxin.
- BBMVs were prepared from rECB larvae in the same manner as from their Cryl Fa-sensitive counterparts.
- resistance to Cry 1 Fa toxin in rECB may be due to less efficient binding of Cry 1 Fa core toxin protein to rECB BBMV receptor (s), as compared to binding to receptors of susceptible larvae. This could manifest as less efficacious for membrane pore formation, since the time that the toxin remains on the receptor is shorter than in susceptible insects.
- Table 1 summarizes the relative binding results from assays using radio-iodinated Cry 1 Fa core toxin protein with BBMV preparations from various insect sources. Percentages indicate the relative amounts of radioactivity bound to BBMVs, with, and without, nonradioactive competitor ligand. 100% values do not represent equal numbers; ECB BBMVs bind less total Cry 1 Fa protein than do FAW BBMVs.
- CrylFa core toxin protein can be radio-labeled using 1251 labeled fluorescein-5-maleimide to specifically alkylate cysteine residues while maintaining insecticidal activity and receptor binding capability.
- the trypsin truncated form of Cryl Fa core toxin contains only a single cysteine residue (corresponding to C205 within Domain 1 of CrylFa), which must comprise the site of radiolabeling. This region constitutes part of the pore structure of the protein and is not thought to be involved in receptor binding.
- the cysteine alkylated CrylFa protein produced herein is insecticidally active against FAW larvae.
- Unlabeled CrylFa protein and unlabeled Cryl Ab protein, but not unlabeled CrylCa protein can displace the binding of radiolabeled CrylFa protein from FAW BBMVs.
- Bioassay data demonstrates that CrylCa is active against both FAW and rFAW larvae, while Cryl Ab is less active against rFAW larvae.
- the biological activities of CrylFa, CrylAb, and CrylCa proteins against FAW and rFAW larvae are conveniently explained and predicted by the BBMV binding assay results. It is therefore one aspect of this invention that combinations of Cry proteins useful in Insect Management strategies may be predicted using competitive binding assays employing CrylFa protein radiolabeled by means of the methods of this invention.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013544801A JP6232288B2 (en) | 2010-12-16 | 2011-12-16 | Biologically active radiolabeled Cry1Fa and receptor binding assay methods |
| BR112013014843A BR112013014843A2 (en) | 2010-12-16 | 2011-12-16 | cry1fa biologically active radiomarker and receptor binding assay methods |
| ES11849627.2T ES2620479T3 (en) | 2010-12-16 | 2011-12-16 | Biologically active radiolabeled Cry1Fa and receptor binding assay methods |
| AU2011343624A AU2011343624B2 (en) | 2010-12-16 | 2011-12-16 | Biologically-active radiolabeled Cry1Fa and receptor binding assay methods |
| RU2013132744/10A RU2601161C2 (en) | 2010-12-16 | 2011-12-16 | BIOLOGICALLY-ACTIVE RADIOLABELED Cry1Fa AND RECEPTOR BINDING ASSAY METHODS |
| KR1020137018411A KR20140032979A (en) | 2010-12-16 | 2011-12-16 | Biologically-active radiolabeled cry1fa and receptor binding assay methods |
| CN201180067859.9A CN103370332B (en) | 2010-12-16 | 2011-12-16 | Biologic activity through radiolabeled Cry1Fa and receptor binding assays |
| EP11849627.2A EP2651966B1 (en) | 2010-12-16 | 2011-12-16 | Biologically-active radiolabeled cry1fa and receptor binding assay methods |
| CA2821255A CA2821255C (en) | 2010-12-16 | 2011-12-16 | Biologically-active radiolabeled cry1fa and receptor binding assay methods |
| ZA2013/03693A ZA201303693B (en) | 2010-12-16 | 2013-05-21 | Biologically-active radiolabeled cry1fa and receptor binding assay methods |
| IL226662A IL226662A (en) | 2010-12-16 | 2013-05-30 | Biologically-active radiolabeled cry1fa and receptor binding assay methods |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42384410P | 2010-12-16 | 2010-12-16 | |
| US61/423,844 | 2010-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2012083099A1 true WO2012083099A1 (en) | 2012-06-21 |
Family
ID=46234902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2011/065322 Ceased WO2012083099A1 (en) | 2010-12-16 | 2011-12-16 | Biologically-active radiolabeled cry1fa and receptor binding assay methods |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8771708B2 (en) |
| EP (1) | EP2651966B1 (en) |
| JP (1) | JP6232288B2 (en) |
| KR (1) | KR20140032979A (en) |
| CN (1) | CN103370332B (en) |
| AR (1) | AR084293A1 (en) |
| AU (1) | AU2011343624B2 (en) |
| BR (1) | BR112013014843A2 (en) |
| CA (1) | CA2821255C (en) |
| ES (1) | ES2620479T3 (en) |
| IL (1) | IL226662A (en) |
| RU (1) | RU2601161C2 (en) |
| WO (1) | WO2012083099A1 (en) |
| ZA (1) | ZA201303693B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12286459B2 (en) | 2018-08-13 | 2025-04-29 | Pioneer Hi-Bred International, Inc. | Insecticidal toxin receptors and methods of use |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2512221B1 (en) * | 2009-12-16 | 2018-11-07 | Dow AgroSciences LLC | Combined use of cry1da and cry1fa proteins for insect resistance management |
| CN103719137B (en) * | 2013-11-15 | 2015-05-13 | 北京大北农科技集团股份有限公司 | Methods of Controlling Pests |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US12031985B2 (en) * | 2018-04-19 | 2024-07-09 | First Light Diagnostics, Inc. | Detection of targets |
| CN118497094A (en) * | 2024-05-13 | 2024-08-16 | 兰州大学 | Bacterial derivative vesicle over-expressing lanthanide binding protein and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5169760A (en) | 1989-07-27 | 1992-12-08 | Mycogen Corporation | Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters |
| US20050064386A1 (en) * | 2003-07-25 | 2005-03-24 | The University Of Georgia Research Foundation, Inc. | Identification of toxin-binding protein involved in resistance to Cry1 toxins, and related screening methods |
| US20060008877A1 (en) | 2003-11-21 | 2006-01-12 | Dow Global Technologies Inc. | Expression systems with sec-system secretion |
| US7338794B2 (en) | 2002-10-08 | 2008-03-04 | Dow Agrosciences Llc | Amended recombinant cells for the production and delivery of gamma interferon as an antiviral agent, adjuvant and vaccine accelerant |
| US20080058262A1 (en) | 2006-05-30 | 2008-03-06 | Rasochova Lada L | rPA optimization |
| US20100017914A1 (en) * | 2007-03-28 | 2010-01-21 | Syngenta Participations Ag | Insecticidal proteins |
| US7681799B2 (en) | 2003-11-13 | 2010-03-23 | Metrologic Instruments, Inc. | Method of reading code symbols using a digital image capturing and processing system employing a micro-computing platform with an event-driven multi-tier software architecture |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2070961C (en) * | 1991-06-14 | 2004-12-07 | Michael Chorev | Thiol-reactive maleimido-based radiolabeling reagents |
| AR025349A1 (en) * | 1999-08-23 | 2002-11-20 | Mycogen Corp | METHODS TO CONTROL GRAY WORM PESTS |
-
2011
- 2011-12-14 AR ARP110104686A patent/AR084293A1/en unknown
- 2011-12-16 BR BR112013014843A patent/BR112013014843A2/en not_active Application Discontinuation
- 2011-12-16 WO PCT/US2011/065322 patent/WO2012083099A1/en not_active Ceased
- 2011-12-16 CN CN201180067859.9A patent/CN103370332B/en not_active Expired - Fee Related
- 2011-12-16 AU AU2011343624A patent/AU2011343624B2/en not_active Ceased
- 2011-12-16 CA CA2821255A patent/CA2821255C/en active Active
- 2011-12-16 RU RU2013132744/10A patent/RU2601161C2/en not_active IP Right Cessation
- 2011-12-16 JP JP2013544801A patent/JP6232288B2/en not_active Expired - Fee Related
- 2011-12-16 ES ES11849627.2T patent/ES2620479T3/en active Active
- 2011-12-16 KR KR1020137018411A patent/KR20140032979A/en not_active Ceased
- 2011-12-16 EP EP11849627.2A patent/EP2651966B1/en active Active
- 2011-12-16 US US13/327,842 patent/US8771708B2/en not_active Expired - Fee Related
-
2013
- 2013-05-21 ZA ZA2013/03693A patent/ZA201303693B/en unknown
- 2013-05-30 IL IL226662A patent/IL226662A/en active IP Right Grant
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5169760A (en) | 1989-07-27 | 1992-12-08 | Mycogen Corporation | Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters |
| US7338794B2 (en) | 2002-10-08 | 2008-03-04 | Dow Agrosciences Llc | Amended recombinant cells for the production and delivery of gamma interferon as an antiviral agent, adjuvant and vaccine accelerant |
| US20050064386A1 (en) * | 2003-07-25 | 2005-03-24 | The University Of Georgia Research Foundation, Inc. | Identification of toxin-binding protein involved in resistance to Cry1 toxins, and related screening methods |
| US7681799B2 (en) | 2003-11-13 | 2010-03-23 | Metrologic Instruments, Inc. | Method of reading code symbols using a digital image capturing and processing system employing a micro-computing platform with an event-driven multi-tier software architecture |
| US20060008877A1 (en) | 2003-11-21 | 2006-01-12 | Dow Global Technologies Inc. | Expression systems with sec-system secretion |
| US20080058262A1 (en) | 2006-05-30 | 2008-03-06 | Rasochova Lada L | rPA optimization |
| US20100017914A1 (en) * | 2007-03-28 | 2010-01-21 | Syngenta Participations Ag | Insecticidal proteins |
Non-Patent Citations (7)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12286459B2 (en) | 2018-08-13 | 2025-04-29 | Pioneer Hi-Bred International, Inc. | Insecticidal toxin receptors and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103370332A (en) | 2013-10-23 |
| KR20140032979A (en) | 2014-03-17 |
| EP2651966A4 (en) | 2014-04-30 |
| EP2651966A1 (en) | 2013-10-23 |
| ES2620479T3 (en) | 2017-06-28 |
| CN103370332B (en) | 2016-02-24 |
| RU2013132744A (en) | 2015-01-27 |
| JP2014503536A (en) | 2014-02-13 |
| JP6232288B2 (en) | 2017-11-15 |
| ZA201303693B (en) | 2014-07-30 |
| RU2601161C2 (en) | 2016-10-27 |
| CA2821255C (en) | 2019-06-04 |
| US8771708B2 (en) | 2014-07-08 |
| IL226662A (en) | 2017-08-31 |
| US20120156803A1 (en) | 2012-06-21 |
| AU2011343624A1 (en) | 2013-06-06 |
| AU2011343624B2 (en) | 2016-08-25 |
| EP2651966B1 (en) | 2017-03-08 |
| CA2821255A1 (en) | 2012-06-21 |
| AR084293A1 (en) | 2013-05-08 |
| BR112013014843A2 (en) | 2017-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chakroun et al. | Susceptibility of Spodoptera frugiperda and S. exigua to Bacillus thuringiensis Vip3Aa insecticidal protein | |
| AU2011343624B2 (en) | Biologically-active radiolabeled Cry1Fa and receptor binding assay methods | |
| Schnepf et al. | Bacillus thuringiensis and its pesticidal crystal proteins | |
| Xue et al. | Cloning and characterization of a novel Cry1A toxin from Bacillus thuringiensis with high toxicity to the Asian corn borer and other lepidopteran insects | |
| Jakka et al. | Cry toxin binding site models and their use in strategies to delay resistance evolution | |
| Ruiz de Escudero et al. | Molecular and insecticidal characterization of a Cry1I protein toxic to insects of the families Noctuidae, Tortricidae, Plutellidae, and Chrysomelidae | |
| Naimov et al. | Bacillus thuringiensis delta-endotoxin Cry1 hybrid proteins with increased activity against the Colorado potato beetle | |
| Gayen et al. | Identification of the bioactive core component of the insecticidal Vip3A toxin peptide of Bacillus thuringiensis | |
| Quan et al. | Critical domains in the specific binding of radiolabeled Vip3Af insecticidal protein to brush border membrane vesicles from Spodoptera spp. and cultured insect cells | |
| BenFarhat-Touzri et al. | Histopathological effects and determination of the putative receptor of Bacillus thuringiensis Cry1Da toxin in Spodoptera littoralis midgut | |
| Dong et al. | Fusing the vegetative insecticidal protein Vip3Aa7 and the N terminus of Cry9Ca improves toxicity against Plutella xylostella larvae | |
| Hernández-Rodríguez et al. | Encapsulation of the Bacillus thuringiensis secretable toxins Vip3Aa and Cry1Ia in Pseudomonas fluorescens | |
| Zhu et al. | Synergism of Bacillus thuringiensis toxin Cry1Ac by a fragment of toxin-binding polycalin from Plutella xylostella | |
| CN118613166A (en) | Compositions and methods for screening insecticidal proteins | |
| Wang et al. | Identification of two Bacillus thuringiensis Cry3Aa toxin-binding aminopeptidase N from Rhynchophorus ferrugineus (Coleoptera: Curculionidae) | |
| AU784994B2 (en) | Pectinophora gossypiella (pink bollworm) bacillus thuringiensis toxin receptor BT-R2 | |
| Osman et al. | Biotechnological production and insecticidal activity of the overexpressed vegetative insecticidal vip3Ah1 gene in Escherichia coli. | |
| Naimov et al. | Carboxy-terminal extension effects on crystal formation and insecticidal properties of Colorado potato beetle-active Bacillus thuringiensis δ-endotoxins | |
| Liao et al. | Binding of Cry δ‐endotoxins to brush border membrane vesicles of Helicoverpa armigera and Helicoverpa punctigera (Lepidoptera: Noctuidae) | |
| Qiu et al. | Solubility enhancement of Cry2Aa crystal through carboxy-terminal extension and synergism between the chimeric protein and Cry1Ac | |
| Zúñiga-Navarrete et al. | Role of GPI-anchored membrane receptors in the mode of action of Bacillus thuringiensis Cry toxins | |
| Mostafa et al. | Cadherin-like receptor from the European corn borer (Ostrinia Nubilalis) for Bacillus thuringiensis cry1A toxins | |
| Villanueva et al. | A Strain of Bacillus thuringiensis Containing a Novel cry7Aa2 Gene That Is Highly Toxic to Leptinotarsa decemlineata (Say)(Coleoptera; Chrysomelidae) | |
| YASSIN et al. | Identification, Isolation and Cloning of cDNA Encoding Aminopeptidase from the Midgut of the Egyetian Cotton Leaf Worm That Serves as a Receptor for CRY Toxin | |
| Maaty | Identification and purification of a novel high-affinity receptor BTR250 from Pink Bollworm (Pectinophora gossypiella) for Bacillus thuringiensis Cry1A toxins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 201180067859.9 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11849627 Country of ref document: EP Kind code of ref document: A1 |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 226662 Country of ref document: IL |
|
| ENP | Entry into the national phase |
Ref document number: 2011343624 Country of ref document: AU Date of ref document: 20111216 Kind code of ref document: A |
|
| REEP | Request for entry into the european phase |
Ref document number: 2011849627 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2011849627 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2821255 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 2013544801 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 20137018411 Country of ref document: KR Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 2013132744 Country of ref document: RU Kind code of ref document: A |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013014843 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: 112013014843 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130613 |
